Moving towards ideal and appropriate models of anticoagulation management service Raphael A - Ann Afr Med
Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation | American Society of Nephrology
Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study | BMC Medicine | Full Text
Advantages and Disadvantages of Novel Oral Anticoagulants | DAIC
Switching between anticoagulant regimes; *half dose for edoxaban;... | Download Scientific Diagram
Advantages and Disadvantages of Novel Oral Anticoagulants | DAIC
Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week - ScienceDirect
JCM | Free Full-Text | Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants | HTML
Recommendation on how to switch between different anticoagulant regimens | Download Table
DOACs: Oral Anticoagulant Treatment of Choice for Pulmonary Embolism? - Endovascular Today
![PDF] When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f01cfb003b76789c5e1bc7cb09440d38d98a84b1/5-Table1-1.png "PDF] When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics | Semantic Scholar")
PDF] When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics | Semantic Scholar
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic - Thrombosis Research
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide | SpringerLink
Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study - Clinical Gastroenterology and Hepatology
Guidance on use of Direct Oral Anti-Coagulants (DOACs) and warfarin in non- valvular Atrial Fibrillation Contents
Rivaroxaban: a fully-subsidised oral anticoagulant
Direct Oral Anticoagulants for Secondary Stroke Prevention - Practical Neurology
Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin | Journal of the American Heart Association
Time for a change? Switching anticoagulants in patients with AF or VTE | Thrombosis Adviser
Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation - Province of British Columbia
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect
Direct Oral Anticoagulants for Secondary Stroke Prevention - Practical Neurology
The market for oral anticoagulants | Nature Reviews Drug Discovery
Recommendations for Switching to and From Rivaroxaban 9 | Download Table
Oral Anticoagulation Management Cheat Sheet: Warfarin, ... | GrepMed
